News » Archives » June 2018

Notre Dame technology licensed worldwide: Hsiri Therapeutics enters into a license and research collaboration agreement with Shionogi &Co., Ltd. for the treatment of mycobacterial diseases

University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM

Read More

New Hope for the Treatment of Diabetic Foot Ulcers

In America, more than a million people suffer from diabetic foot ulcers.

In Latin, SalvePeds means “saving feet.” 

And in SalvePeds, a new IDEA Center startup managed and marketed by a team of graduate students at the University of Notre Dame, patients may soon have a more effective option to treat diabetic foot ulcers and prevent some of the 100,000 amputations the condition necessitates every year.…

Read More